Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis

Clinical Immunology

Volumn 128, Issue 3, 2008, Pages 382-391

  Harp, Christopher T ^a   Lovett Racke, Amy E ^b   Racke, Michael K ^b   Frohman, Elliot M ^a   Monson, Nancy L ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antigen presentation; Autoimmunity; B cells; Multiple sclerosis

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN; T LYMPHOCYTE RECEPTOR;

ADULT; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; B-LYMPHOCYTE SUBSETS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODEOXYRIBONUCLEOTIDES; UP-REGULATION;

EID: 49149111862     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.05.002     Document Type: Article

References (54)

1. Antel J., and Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J. Neuroimmunol. 180 (2006) 3-8
2. Villar L.M., Sadaba M.C., Roldan E., Masjuan J., Gonzalez-Porque P., Villarrubia N., Espino M., Garcia-Trujillo J.A., Bootello A., and Alvarez-Cermeno J.C. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115 (2005) 187-194
3. Mathiesen T., von Holst H., Fredrikson S., Wirsen G., Hederstedt B., Norrby E., Sundqvist V.A., and Wahren B. Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system. J. Neurol. 236 (1989) 238-242
4. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., and Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 122 Pt 11 (1999) 2089-2100
5. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., and Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 349 (2003) 139-145
6. Genain C.P., Cannella B., Hauser S.L., and Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5 (1999) 170-175
7. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F., Poewe W., and Berger T. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 122 Pt 11 (1999) 2047-2056
8. Warrington A.E., Asakura K., Bieber A.J., Ciric B., Van Keulen V., Kaveri S.V., Kyle R.A., Pease L.R., and Rodriguez M. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6820-6825
9. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., Polman C.H., Miller D.H., Montalban X., Barkhof F., Bauer L., Dahms S., Lindberg R., Kappos L., and Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 356 (2007) 371-378
10. Tumanov A., Kuprash D., Lagarkova M., Grivennikov S., Abe K., Shakhov A., Drutskaya L., Stewart C., Chervonsky A., and Nedospasov S. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 17 (2002) 239-250
11. Mamula M.J., Fatenejad S., and Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J. Immunol. 152 (1994) 1453-1461
12. Yan J., Harvey B.P., Gee R.J., Shlomchik M.J., and Mamula M.J. B cells drive early T cell autoimmunity in vivo prior to dendritic cell-mediated autoantigen presentation. J. Immunol. 177 (2006) 4481-4487
13. Shen H., Whitmire J.K., Fan X., Shedlock D.J., Kaech S.M., and Ahmed R. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J. Immunol. 170 (2003) 1443-1451
14. + T cells in vivo in the absence of other professional antigen-presenting cells in a CD154-CD40-dependent manner. Eur. J. Immunol. 35 (2005) 1097-1105
15. Rivera A., Chen C.C., Ron N., Dougherty J.P., and Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13 (2001) 1583-1593
16. Roth R., Nakamura T., and Mamula M.J. B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. J. Immunol. 157 (1996) 2924-2931
17. O'Neill S.K., Shlomchik M.J., Glant T.T., Cao Y., Doodes P.D., and Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 174 (2005) 3781-3788
18. Homann D., Tishon A., Berger D.P., Weigle W.O., von Herrath M.G., and Oldstone M.B. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J. Virol. 72 (1998) 9208-9216
19. Crawford A., Macleod M., Schumacher T., Corlett L., and Gray D. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 176 (2006) 3498-3506
20. Duda P.W., Krieger J.I., Schmied M.C., Balentine C., and Hafler D.A. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. J. Immunol. 165 (2000) 7300-7307
21. Kurt-Jones E.A., Liano D., HayGlass K.A., Benacerraf B., Sy M.S., and Abbas A.K. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J. Immunol. 140 (1988) 3773-3778
22. Epstein M.M., Di Rosa F., Jankovic D., Sher A., and Matzinger P. Successful T cell priming in B cell-deficient mice. J. Exp. Med. 182 (1995) 915-922
23. Ronchese F., and Hausmann B. B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J. Exp. Med. 177 (1993) 679-690
24. Linton P.J., Harbertson J., and Bradley L.M. A critical role for B cells in the development of memory CD4 cells. J. Immunol. 165 (2000) 5558-5565
25. Serreze D.V., Chapman H.D., Varnum D.S., Hanson M.S., Reifsnyder P.C., Richard S.D., Fleming S.A., Leiter E.H., and Shultz L.D. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med. 184 (1996) 2049-2053
26. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., and Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
27. Cross A.H., Stark J.L., Lauber J., Ramsbottom M.J., and Lyons J.A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180 (2006) 63-70
28. Genc K., Dona D.L., and Reder A.T. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J. Clin. Invest. 99 (1997) 2664-2671
29. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., Delgado J.C., Gribben J.G., and Nadler L.M. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100 (1997) 2757-2765
30. Bar-Or A., Oliveira E.M., Anderson D.E., Krieger J.I., Duddy M., O'Connor K.C., and Hafler D.A. Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J. Immunol. 167 (2001) 5669-5677
31. Fecteau J.F., and Neron S. CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J. Immunol. 171 (2003) 4621-4629
32. Mardiney III M., Brown M.R., and Fleisher T.A. Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals. Cytometry 26 (1996) 305-310
33. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., and Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 101 (1998) 725-730
34. Jingwu Z., Medaer R., Hashim G.A., Chin Y., van den Berg-Loonen E., and Raus J.C. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol. 32 (1992) 330-338
35. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., and Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1 (1971) 242-248
36. Amanna I.J., and Slifka M.K. Quantitation of rare memory B cell populations by two independent and complementary approaches. J. Immunol. Methods 317 (2006) 175-185
37. Karandikar N.J., Crawford M.P., Yan X., Ratts R.B., Brenchley J.M., Ambrozak D.R., Lovett-Racke A.E., Frohman E.M., Stastny P., Douek D.C., Koup R.A., and Racke M.K. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109 (2002) 641-649
38. Bryant P., and Ploegh H. Class II MHC peptide loading by the professionals. Curr. Opin. Immunol. 16 (2004) 96-102
39. Becher B., Prat A., and Antel J.P. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29 (2000) 293-304
40. Hauser S.L.e.a. A phase II randomized, placebo-controlled trial of rituximab in adult with relapsing remitting multiple sclerosis. Neurology 68 (2007)
41. Banchereau J., de Paoli P., Valle A., Garcia E., and Rousset F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251 (1991) 70-72
42. Lapointe R., Bellemare-Pelletier A., Housseau F., Thibodeau J., and Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 63 (2003) 2836-2843
43. Jiang W., Lederman M.M., Harding C.V., Rodriguez B., Mohner R.J., and Sieg S.F. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur. J. Immunol. 37 (2007) 2205-2213
44. Greer J.M., Csurhes P.A., Cameron K.D., McCombe P.A., Good M.F., and Pender M.P. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120 Pt 8 (1997) 1447-1460
45. Arbour N., Lapointe R., Saikali P., McCrea E., Regen T., and Antel J.P. A new clinically relevant approach to expand myelin specific T cells. J. Immunol. Methods 310 (2006) 53-61
46. Lambracht-Washington D., O'Connor K.C., Cameron E.M., Jowdry A., Ward E.S., Frohman E., Racke M.K., and Monson N.L. Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J. Neuroimmunol. 186 (2007) 164-176
47. Stuve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., Frohman E.M., Phillips J.T., Arendt G., Hemmer B., Monson N.L., and Racke M.K. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59 (2006) 743-747
48. Seamons A., Perchellet A., and Goverman J. Endogenous myelin basic protein is presented in the periphery by both dendritic cells and resting B cells with different functional consequences. J. Immunol. 177 (2006) 2097-2106
49. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Kim H.J., and Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178 (2007) 6092-6099
50. Mizoguchi A., and Bhan A.K. A case for regulatory B cells. J. Immunol. 176 (2006) 705-710
51. Mauri C., Gray D., Mushtaq N., and Londei M. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197 (2003) 489-501
52. Schultze J.L., Cardoso A.A., Freeman G.J., Seamon M.J., Daley J., Pinkus G.S., Gribben J.G., and Nadler L.M. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8200-8204
53. Tennakoon D.K., Mehta R.S., Ortega S.B., Bhoj V., Racke M.K., and Karandikar N.J. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J. Immunol. 176 (2006) 7119-7129
54. Harp C., Lee J., Lambracht-Washington D., Cameron E., Olsen G., Frohman E., Racke M., and Monson N. Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection. J. Neuroimmunol. 183 (2007) 189-199